Indole and Indazole TLR7/8/9 Inhibitors With Better Bioavailability

Solution Overview

Problem

Existing compounds for modulating Toll-like receptors (TLR7, TLR8, and TLR9) lack desirable stability, bioavailability, and therapeutic index, limiting their effectiveness in treating inflammatory, autoimmune, and allergic diseases.

Innovation Solution

Development of a new class of indole and indazole compounds that act as inhibitors of TLR7/8/9 signaling, offering improved stability, bioavailability, and therapeutic index.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing compounds are used to modulate TLR7/8/9, then TLR signaling inhibition is achieved, but stability and bioavailability are insufficient

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by systematically modifying chemical parameters of the indole and indazole core structures, including substitution patterns at positions 1, 2, 3, 4, 5, 6, 7 of the indole ring and variations in the R1-R6 substituents. These chemical parameter modifications optimize both the stability and bioavailability of the compounds while maintaining TLR7/8/9 inhibition activity.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite material principles by combining the indole or indazole core structure with diverse substituent groups including heterocyclic rings, aromatic systems, and aliphatic chains. This composite molecular architecture integrates multiple functional elements that collectively enhance stability, improve bioavailability, and maintain pharmacological activity.

Inventive Principle:
Principle #40Composite materials

2Reliability

If existing compounds are used to modulate TLR7/8/9, then TLR signaling inhibition is achieved, but therapeutic index is insufficient

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent optimizes the therapeutic index by adjusting chemical parameters to achieve selective TLR7/8/9 inhibition with reduced off-target effects. The substitution patterns and molecular properties are tuned to improve the ratio between effective concentration and toxic concentration, thereby enhancing the therapeutic window.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality principles by introducing specific substituents at particular positions on the indole/indazole ring system. Each substituent is strategically placed to enhance specific properties: some positions are optimized for binding affinity to TLR7/8/9, while others are optimized for metabolic stability and reduced toxicity, thereby improving the overall therapeutic index.

Inventive Principle:
Principle #3Local quality

Data Source

PatentEP3870583B1Substituted indole and indazole compounds
Publication Date: 2026.04.22
  • EP3870583B1 patent drawing
  • EP3870583B1 patent drawing
  • EP3870583B1 patent drawing

AI summary

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR1 or N; and G, A, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.